Developer docs
API playgroundTry for free, no card

Search company profiles

CG Oncology

Full company profile

uuid00005u6

Namestring
CG Oncology
Legal namestring
CG Oncology, Inc.
Websiteurl
cgoncology.com
Company typeenum
Public
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncolytic immunotherapy, bladder cancer therapeutics, biopharmaceutical drug development, clinical stage oncology, investigational urology drugs
Industry2 codes
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAFAK
Gastrointestinal Oncology
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bladder Cancer Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing (Asia ex-China)
TypeLicensing Royalties
Description

Exclusive development and commercialization license to Kissei Pharmaceutical Co., Ltd. for cretostimogene in Japan, South Korea, Taiwan and other Asian countries (excluding China). Deal valued up to $140 million: $10M upfront licensing fee, up to $100M in development and commercial milestones, $30M equity investment, plus tiered royalties on sales in licensed territories. First $10M development milestone triggered December 2021 upon first patient dosed in Japan.

cgoncology.com
2Pre-revenue commercial product
TypeOne Time License
Description

No approved product yet; minimal revenue ($4.0M in FY2025, $1.08M in Q1 2026) primarily from collaboration activities. Future revenue expected from direct US commercialization of cretostimogene following FDA approval (BLA completion targeted Q4 2026).

simplywall.st
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CG Oncology is developing cretostimogene grenadenorepvec (formerly CG0070), an investigational intravesically delivered oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). The drug uses a genetically modified adenovirus type 5 backbone with a cancer-selective E2F promoter driving GM-CSF expression to selectively replicate in tumor cells with defective retinoblastoma (Rb) pathways, causing tumor lysis and stimulating systemic anti-tumor immunity. The company is preparing to file a Biologics License Application (BLA) targeted for Q4 2026 for high-risk BCG-unresponsive NMIBC.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 75.5% (83/110) complete response rate at any time in BOND-003 Phase 3 Cohort C (cretostimogene monotherapy, HR BCG-unresponsive NMIBC)
+6 more records
Product overview1 text field

CG Oncology is a late-stage clinical biopharmaceutical company singularly focused on developing and commercializing cretostimogene grenadenorepvec (formerly CG0070) as a potential backbone bladder-sparing therapeutic for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Rather than operating as a multi-asset platform, the company's offering centers on a single investigational oncolytic immunotherapy evaluated across an integrated clinical development program of complementary trials: the BOND-003 Phase 3 monotherapy program for high-risk BCG-unresponsive NMIBC, the PIVOT-006 Phase 3 adjuvant program for intermediate-risk NMIBC, and the CORE-008 Phase 2 combination program with gemcitabine in high-risk NMIBC, all of which together form the company's pipeline architecture. The company is preparing for FDA approval and commercialization of cretostimogene, with Biologics License Application (BLA) completion expected in Q4 2026 and has an Expanded Access Program in North America.

Product and service2 records
1Cretostimogene Grenadenorepvec (formerly CG0070)
CategoryInvestigational Oncolytic Immunotherapy Drug Candidate
Description

Lead investigational intravesically delivered oncolytic immunotherapy (OIT) with a dual mechanism of action: selectively replicates inside bladder tumor cells with dysfunctional retinoblastoma (Rb) pathways to cause tumor cell lysis and immunogenic cell death, and encodes GM-CSF to stimulate a systemic anti-tumor immune response. Evaluated in over 600 patients with non-muscle invasive bladder cancer (NMIBC). Safety and efficacy have not been established by the FDA or any other health authority; investigational drug candidate awaiting BLA completion targeted for Q4 2026.

2Expanded Access Program (North America)
CategoryPre-Approval Patient Access Program
Description

Pre-approval patient access pathway in North America providing cretostimogene grenadenorepvec to BCG-unresponsive non-muscle invasive bladder cancer patients who meet program eligibility requirements, prior to FDA approval.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Pegasus Park (Tower)
Strategic tierCoreTypeOthersAnnounced on2026-05-19
Description

CG Oncology expanded its footprint at Pegasus Park in Dallas in May 2026, leasing space on the tower's 16th floor alongside Highlander Health and LH Capital. Pegasus Park is positioned as a premier innovation hub where biotech, venture capital, and philanthropic leaders collaborate.

dallasinnovates.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Co-sponsored NMIBC Research Fellowship program with CG Oncology, awarding annual grants of up to $50,000 each to early-career investigators. First annual program launched May 2025; second annual awarded May 2026 to Patrick Hensley, MD (University of Kentucky) and Daniel Joyce, MD, MS (Vanderbilt University Medical Center). SUO-CTC is a clinical research investigator network of 750+ members from 350+ clinical sites.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-05-01
Description

CG Oncology is a member company of the American Biotech Innovation Alliance (ABIA), a national coalition of approximately 50 biotech companies (including Moderna and Gamida Cell) formed in early May 2025 by Patroski Lawson of KPM Group. ABIA aims to develop a national policy strategy to strengthen American biotech innovation amid rising competition from China.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-12-20
Description

Lead investigator site partnership with University of Pennsylvania (Trinity J. Bivalacqua, M.D., Ph.D., Professor of Urology and Oncology at the Perelman Center for Advanced Medicine) for Phase 3 BOND-003 study of cretostimogene in HR BCG-unresponsive NMIBC. Dr. Bivalacqua also serves as lead investigator for CORE-008 Cohort CX.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-22
Description

Clinical trial collaboration to evaluate CG0070 (cretostimogene) in combination with Roche's anti-PD-L1 therapy atezolizumab in a Phase 1/2 study for various advanced solid tumors. CG Oncology sponsors the study; Roche provides atezolizumab.

6Bristol Myers Squibb (BMS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-09
Description

Clinical trial collaboration to evaluate CG0070 (cretostimogene) in combination with Bristol Myers Squibb's anti-PD-1 therapy OPDIVO (nivolumab) in a Phase 1/2 study for metastatic urothelial cancer. CG Oncology sponsors the study; BMS provides nivolumab.

cgoncology.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-11-12
Description

Investigator-initiated Phase 1b study led by Dr. Roger Li at Moffitt Cancer Center evaluating CG0070 + nivolumab combination as neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients. Multi-center trial with up to 30 patients. CORE-2 study (NCT04610671).

8Kissei Pharmaceutical Co., Ltd.
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-03-26
Description

Exclusive development and commercialization license for cretostimogene grenadenorepvec in Japan, South Korea, Taiwan and other Asian countries (excluding China). Deal valued at up to $140 million plus royalties, including a $10M upfront licensing fee and $30M equity investment. CG Oncology retains rights for US and rest of world. First $10M development milestone triggered December 2021 upon first patient dosed in Japan in Phase 3 BOND-003 study.

cgoncology.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-11-28
Description

Clinical trial collaboration to evaluate CG0070 (cretostimogene) in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in Phase 2 CORE1 study for BCG-unresponsive NMIBC. CG Oncology sponsors the study; Merck provides pembrolizumab. Additional details of the collaboration not disclosed. Multiple data readouts presented at AUA, ASCO, AACR, SITC (2018–2022); fully enrolled with 35 patients; long-term data published in Nature Medicine June 2024.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ferring markets ADSTILADRIN (nadofaragene firadenovec), an FDA-approved intravesical gene therapy for high-risk BCG-unresponsive NMIBC. Directly competes with cretostimogene in the same lead indication and prescriber base (urologists), and represents the most direct competitive threat in the BCG-unresponsive setting.

TypeDirect peer
Description

ImmunityBio received FDA approval for ANKTIVA (N-803/ nogapendekin alfa inbakicept-pmln) plus BCG for BCG-unresponsive NMIBC with CIS. Directly competes with CG Oncology for the same HR BCG-unresponsive NMIBC patient population and is now an established alternative in urology practices.

TypeEmerging player
Description

Replimune develops oncolytic immunotherapies (RP1, RP2, RP3) based on a modified herpes simplex virus platform. While focused on skin cancers rather than bladder, it is one of the few clinical-stage competitors in the broader oncolytic virus modality that CG Oncology's cretostimogene belongs to.

TypeBroad incumbent
Description

AstraZeneca markets IMFINZI (durvalumab), an FDA-approved checkpoint inhibitor studied in NMIBC, and operates broadly in oncology including bladder cancer. Comparable as a checkpoint inhibitor developer for urologic cancers and a potential combination or competitive partner to cretostimogene.

TypeBroad incumbent
Description

Merck is the maker of KEYTRUDA (pembrolizumab), which CG Oncology has combined with cretostimogene in the CORE-001 Phase 2 trial. Merck is a leading immuno-oncology incumbent whose checkpoint inhibitor is both a collaboration partner and a competitive threat in advanced bladder cancer.

6Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets OPDIVO (nivolumab), an anti-PD-1 checkpoint inhibitor combined with cretostimogene in the CORE-2 study in MIBC. Comparable as a large immuno-oncology incumbent with overlapping bladder cancer indications and a clinical combination partner for cretostimogene.

TypeBroad incumbent
Description

Roche markets TECENTRIQ (atezolizumab), an anti-PD-L1 checkpoint inhibitor combined with cretostimogene in an investigator-sponsored Phase 1/2 study. Comparable as a global oncology incumbent and combination partner whose checkpoint inhibitors compete in advanced urologic cancers.

8Kissei Pharmaceutical
TypeRegional player
Description

Kissei holds exclusive Asia ex-China development and commercialization rights for cretostimogene under a deal valued at up to $140M plus royalties. Comparable as the regional licensee and validated urology commercial partner in Japan, South Korea, Taiwan and other Asian markets.

9Targovax
TypeEmerging player
Description

Targovax develops oncolytic virus-based immunotherapies (ONCOS-102) for solid tumors. While focused on different indications, it is a clinical-stage peer in the same oncolytic immunotherapy modality that cretostimogene belongs to.

TypeEmerging player
Description

Aprea Therapeutics is a clinical-stage oncology biopharmaceutical company developing small molecule and biologic therapies. Comparable as a similarly sized late clinical-stage oncology peer with comparable development-stage profile and biopharma industry positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CG Oncology

Bladder Cancer Therapeuticscgoncology.com

CG Oncology firmographics

Firmographics
Name
CG Oncology
Legal name
CG Oncology, Inc.
Website
https://cgoncology.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

CG Oncology industry classification

Industry
Product category
Bladder Cancer Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAFAK
Gastrointestinal Oncology

Keywords

  • Oncolytic immunotherapy
  • Bladder cancer therapeutics
  • Biopharmaceutical drug development
  • Clinical stage oncology
  • Investigational urology drugs

Where CG Oncology is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Markets served

CG Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Out-licensing (Asia ex-China): Exclusive development and commercialization license to Kissei Pharmaceutical Co., Ltd. for cretostimogene in Japan, South Korea, Taiwan and other Asian countries (excluding China). Deal valued up to $140 million: $10M upfront licensing fee, up to $100M in development and commercial milestones, $30M equity investment, plus tiered royalties on sales in licensed territories. First $10M development milestone triggered December 2021 upon first patient dosed in Japan.
  2. Pre-revenue commercial product: No approved product yet; minimal revenue ($4.0M in FY2025, $1.08M in Q1 2026) primarily from collaboration activities. Future revenue expected from direct US commercialization of cretostimogene following FDA approval (BLA completion targeted Q4 2026).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

CG Oncology product offering

Product offering

Core offering

CG Oncology is developing cretostimogene grenadenorepvec (formerly CG0070), an investigational intravesically delivered oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). The drug uses a genetically modified adenovirus type 5 backbone with a cancer-selective E2F promoter driving GM-CSF expression to selectively replicate in tumor cells with defective retinoblastoma (Rb) pathways, causing tumor lysis and stimulating systemic anti-tumor immunity. The company is preparing to file a Biologics License Application (BLA) targeted for Q4 2026 for high-risk BCG-unresponsive NMIBC.

Product overview

CG Oncology is a late-stage clinical biopharmaceutical company singularly focused on developing and commercializing cretostimogene grenadenorepvec (formerly CG0070) as a potential backbone bladder-sparing therapeutic for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Rather than operating as a multi-asset platform, the company's offering centers on a single investigational oncolytic immunotherapy evaluated across an integrated clinical development program of complementary trials: the BOND-003 Phase 3 monotherapy program for high-risk BCG-unresponsive NMIBC, the PIVOT-006 Phase 3 adjuvant program for intermediate-risk NMIBC, and the CORE-008 Phase 2 combination program with gemcitabine in high-risk NMIBC, all of which together form the company's pipeline architecture. The company is preparing for FDA approval and commercialization of cretostimogene, with Biologics License Application (BLA) completion expected in Q4 2026 and has an Expanded Access Program in North America.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cretostimogene Grenadenorepvec (formerly CG0070) Lead investigational intravesically delivered oncolytic immunotherapy (OIT) with a dual mechanism of action: selectively replicates inside bladder tumor cells with dysfunctional retinoblastoma (Rb) pathways to cause tumor cell lysis and immunogenic cell death, and encodes GM-CSF to stimulate a systemic anti-tumor immune response. Evaluated in over 600 patients with non-muscle invasive bladder cancer (NMIBC). Safety and efficacy have not been established by the FDA or any other health authority; investigational drug candidate awaiting BLA completion targeted for Q4 2026.
  • Expanded Access Program (North America) Pre-approval patient access pathway in North America providing cretostimogene grenadenorepvec to BCG-unresponsive non-muscle invasive bladder cancer patients who meet program eligibility requirements, prior to FDA approval.

Quantifiable outcome

  • 75.5% (83/110) complete response rate at any time in BOND-003 Phase 3 Cohort C (cretostimogene monotherapy, HR BCG-unresponsive NMIBC)
  • +6 more outcomes

Companies that use CG Oncology

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

CG Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

CG Oncology partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

  • Pegasus Park (Tower)coreOthers · 19 May 2026CG Oncology expanded its footprint at Pegasus Park in Dallas in May 2026, leasing space on the tower's 16th floor alongside Highlander Health and LH Capital. Pegasus Park is positioned as a premier innovation hub where biotech, venture capital, and philanthropic leaders collaborate.
  • Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC)coreStrategic or Co-development Partner · 18 December 2025Co-sponsored NMIBC Research Fellowship program with CG Oncology, awarding annual grants of up to $50,000 each to early-career investigators. First annual program launched May 2025; second annual awarded May 2026 to Patrick Hensley, MD (University of Kentucky) and Daniel Joyce, MD, MS (Vanderbilt University Medical Center). SUO-CTC is a clinical research investigator network of 750+ members from 350+ clinical sites.
  • American Biotech Innovation Alliance (ABIA)minorGTM or Marketing Partner · 1 May 2025CG Oncology is a member company of the American Biotech Innovation Alliance (ABIA), a national coalition of approximately 50 biotech companies (including Moderna and Gamida Cell) formed in early May 2025 by Patroski Lawson of KPM Group. ABIA aims to develop a national policy strategy to strengthen American biotech innovation amid rising competition from China.
  • University of Pennsylvania (Trinity Bivalacqua, M.D. — Phase 3 BOND-003)flagshipStrategic or Co-development Partner · 20 December 2021Lead investigator site partnership with University of Pennsylvania (Trinity J. Bivalacqua, M.D., Ph.D., Professor of Urology and Oncology at the Perelman Center for Advanced Medicine) for Phase 3 BOND-003 study of cretostimogene in HR BCG-unresponsive NMIBC. Dr. Bivalacqua also serves as lead investigator for CORE-008 Cohort CX.
  • RochecoreStrategic or Co-development Partner · 22 September 2021Clinical trial collaboration to evaluate CG0070 (cretostimogene) in combination with Roche's anti-PD-L1 therapy atezolizumab in a Phase 1/2 study for various advanced solid tumors. CG Oncology sponsors the study; Roche provides atezolizumab.
  • Bristol Myers Squibb (BMS)coreStrategic or Co-development Partner · 9 September 2021Clinical trial collaboration to evaluate CG0070 (cretostimogene) in combination with Bristol Myers Squibb's anti-PD-1 therapy OPDIVO (nivolumab) in a Phase 1/2 study for metastatic urothelial cancer. CG Oncology sponsors the study; BMS provides nivolumab.
  • Moffitt Cancer Center (Roger Li, M.D.)flagshipStrategic or Co-development Partner · 12 November 2020Investigator-initiated Phase 1b study led by Dr. Roger Li at Moffitt Cancer Center evaluating CG0070 + nivolumab combination as neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients. Multi-center trial with up to 30 patients. CORE-2 study (NCT04610671).
  • Kissei Pharmaceutical Co., Ltd.flagshipOEM/ Whitelabel/ Licensing Partner · 26 March 2020Exclusive development and commercialization license for cretostimogene grenadenorepvec in Japan, South Korea, Taiwan and other Asian countries (excluding China). Deal valued at up to $140 million plus royalties, including a $10M upfront licensing fee and $30M equity investment. CG Oncology retains rights for US and rest of world. First $10M development milestone triggered December 2021 upon first patient dosed in Japan in Phase 3 BOND-003 study.
  • Merck (MSD)flagshipStrategic or Co-development Partner · 28 November 2018Clinical trial collaboration to evaluate CG0070 (cretostimogene) in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in Phase 2 CORE1 study for BCG-unresponsive NMIBC. CG Oncology sponsors the study; Merck provides pembrolizumab. Additional details of the collaboration not disclosed. Multiple data readouts presented at AUA, ASCO, AACR, SITC (2018–2022); fully enrolled with 35 patients; long-term data published in Nature Medicine June 2024.

Scale indicators13 records

Recent moves10 records

Expansion highlights8 records

CG Oncology competitors and assessment

Company assessment

Direct peers

  • Ferring Pharmaceuticals: Ferring markets ADSTILADRIN (nadofaragene firadenovec), an FDA-approved intravesical gene therapy for high-risk BCG-unresponsive NMIBC. Directly competes with cretostimogene in the same lead indication and prescriber base (urologists), and represents the most direct competitive threat in the BCG-unresponsive setting.
  • ImmunityBio: ImmunityBio received FDA approval for ANKTIVA (N-803/ nogapendekin alfa inbakicept-pmln) plus BCG for BCG-unresponsive NMIBC with CIS. Directly competes with CG Oncology for the same HR BCG-unresponsive NMIBC patient population and is now an established alternative in urology practices.

Emerging players

  • Replimune Group: Replimune develops oncolytic immunotherapies (RP1, RP2, RP3) based on a modified herpes simplex virus platform. While focused on skin cancers rather than bladder, it is one of the few clinical-stage competitors in the broader oncolytic virus modality that CG Oncology's cretostimogene belongs to.
  • Targovax: Targovax develops oncolytic virus-based immunotherapies (ONCOS-102) for solid tumors. While focused on different indications, it is a clinical-stage peer in the same oncolytic immunotherapy modality that cretostimogene belongs to.
  • Aprea Therapeutics: Aprea Therapeutics is a clinical-stage oncology biopharmaceutical company developing small molecule and biologic therapies. Comparable as a similarly sized late clinical-stage oncology peer with comparable development-stage profile and biopharma industry positioning.

Broad incumbents

  • AstraZeneca: AstraZeneca markets IMFINZI (durvalumab), an FDA-approved checkpoint inhibitor studied in NMIBC, and operates broadly in oncology including bladder cancer. Comparable as a checkpoint inhibitor developer for urologic cancers and a potential combination or competitive partner to cretostimogene.
  • Merck & Co. (MSD): Merck is the maker of KEYTRUDA (pembrolizumab), which CG Oncology has combined with cretostimogene in the CORE-001 Phase 2 trial. Merck is a leading immuno-oncology incumbent whose checkpoint inhibitor is both a collaboration partner and a competitive threat in advanced bladder cancer.
  • Bristol Myers Squibb: BMS markets OPDIVO (nivolumab), an anti-PD-1 checkpoint inhibitor combined with cretostimogene in the CORE-2 study in MIBC. Comparable as a large immuno-oncology incumbent with overlapping bladder cancer indications and a clinical combination partner for cretostimogene.
  • Roche: Roche markets TECENTRIQ (atezolizumab), an anti-PD-L1 checkpoint inhibitor combined with cretostimogene in an investigator-sponsored Phase 1/2 study. Comparable as a global oncology incumbent and combination partner whose checkpoint inhibitors compete in advanced urologic cancers.

Regional players

  • Kissei Pharmaceutical: Kissei holds exclusive Asia ex-China development and commercialization rights for cretostimogene under a deal valued at up to $140M plus royalties. Comparable as the regional licensee and validated urology commercial partner in Japan, South Korea, Taiwan and other Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

CG Oncology social profiles

Digital presence

CG Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CG Oncology leadership team

Management profile

Number of profiles

Profiles12 records

CG Oncology subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CG Oncology funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CG Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CG Oncology

What does CG Oncology do?

CG Oncology is developing cretostimogene grenadenorepvec (formerly CG0070), an investigational intravesically delivered oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). The drug uses a genetically modified adenovirus type 5 backbone with a cancer-selective E2F promoter driving GM-CSF expression to selectively replicate in tumor cells with defective retinoblastoma (Rb) pathways, causing tumor lysis and stimulating systemic anti-tumor immunity. The company is preparing to file a Biologics License Application (BLA) targeted for Q4 2026 for high-risk BCG-unresponsive NMIBC.

Is CG Oncology a public or private company?

CG Oncology is a public company. It is classified as public and is currently operating.

When was CG Oncology founded?

CG Oncology was founded in 2010. It employs 101 to 250 people.

Where is CG Oncology based?

CG Oncology is headquartered in Dallas, United States, in the North America region.

How does CG Oncology make money?

Two revenue lines are on record. Out-licensing (Asia ex-China) is the primary driver. The others are pre-revenue commercial product.

Who are CG Oncology's main competitors?

Direct peers on record are Ferring Pharmaceuticals and ImmunityBio. Emerging players are Replimune Group, Targovax and Aprea Therapeutics. Broad incumbents are AstraZeneca, Merck & Co. (MSD), Bristol Myers Squibb and Roche. Kissei Pharmaceutical is listed as a regional player.

Does CG Oncology have an API?

No public API is recorded for CG Oncology.

What industry is CG Oncology in?

CG Oncology's product category is Bladder Cancer Therapeutics. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAKAFAK, Gastrointestinal Oncology. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comGuggenheim raises CG Oncology stock price target on trial resultsGuggenheim raised its price target on CG Oncology to $120 from $89, maintaining a Buy rating. The firm increased its risk-adjusted estimate for cretostimogene to $3.0 billion by 2035, up from $2.1 billion, after the PIVOT-006 trial results. It expects a U.S. launch by year-end 2027.Defense WorldCG Oncology (NASDAQ:CGON) Stock Price Target Raised at Morgan StanleyMorgan Stanley raised its price target on CG Oncology to $117 from $102, keeping an overweight rating. The company reported a loss of $0.64 per share for the quarter, beating estimates, and insiders purchased shares. Analysts have a consensus price target of $98.78.TIKRCG Oncology’s CEO Called Its Trial Results a “Defining Milestone.” Then He and Another Executive Bought $2.7 Million of StockCG Oncology CEO Arthur Kuan bought $2.4 million of company stock on Nov. 18, and CCO Isabel Kalofonos bought shares the same day, two days after a Phase 3 trial win and a downgrade. Analysts expect $411 million in 2028 revenue, but the first FDA filing is pushed into 2027. The next tests are full PIVOT-006 data on Dec. 2 and a 2027 filing.Nate[GAM] CG온콜로지 사상 최고가 ② 승인된 보조요법 없는 5만명 시장 정조준 : 네이트 뉴스CG Oncology reported positive Phase 3 results for its adeno-viral immunotherapy creto-stimomab in NMIBC, with a 68% reduction in recurrence risk. The company plans to file two BLAs in 2027, targeting BCG-refractory and intermediate/high-risk Ta NMIBC. The stock hit a record high, with analysts averaging a $104.33 target.Nate[GAM] CG온콜로지 사상 최고가 ① 방광암 신약 3상서 재발 위험 68% 감소 : 네이트 뉴스CG Oncology's stock hit a record high after its Phase 3 trial of the bladder cancer drug cretostimogene showed a 68% lower recurrence risk versus control. The trial met its primary endpoint, with no serious adverse events, and analysts raised price targets. The company expects regulatory approval to follow.Labiotech.euOncology biotech news: Key moves to watch in November 2026Oncology biotech news for November 2026 covers eight developments, including CG Oncology's positive phase 3 data for cretostimogene in bladder cancer, Dren Bio's $350 million financing, and FDA approvals for Roche's Wilserdly and Sellas' vaccine. The roundup also notes Summit's FDA rejection for ivonescimab and Eli Lilly's acquisitions and partnerships.TradingViewKey facts: 68% lower recurrence risk; record close; targets raisedCG Oncology reported Phase 3 data for cretostimogene showing a 68% lower recurrence risk after 17 months. Shares rose nearly 14% to a record $84.78, up 346% from IPO price, and four firms raised price targets.TradingViewJP Morgan maintains CG Oncology at Overweight, raises price target to $113 from $96JP Morgan maintained CG Oncology at Overweight and raised its price target to $113 from $96, a 17.7% increase. The target implies a 33.3% upside from the Nov 16 close of $84.78. Recent analyst price targets range from $89 to $115.TradingViewTruist Securities maintains CG Oncology at Buy, raises price target to $100 from $85Truist Securities maintained CG Oncology at Buy and raised its price target to $100 from $85, a 17.6% increase. The target implies an 18.0% upside from the Nov 16 close of $84.78. Recent analyst price targets range from $89 to $115.TradingViewWedbush maintains CG Oncology at Outperform, raises price target to $91 from $84Wedbush maintained CG Oncology at Outperform and raised its price target to $91 from $84, an 8.3% increase. The target implies 7.3% upside from the Nov 16 close of $84.78. Recent analyst price targets range from $84 to $115.